Results 171 to 180 of about 9,288 (216)
Some of the next articles are maybe not open access.

Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor

European Respiratory Journal
Graphical abstract Before elexacaftor/tezacaftor/ivacaftor (“Pre-ETI”), bronchi with cylindrical dilatations (left) and those with varicose or saccular dilatations (right) have an enlarged diameter compared with the adjacent artery (B/A≥1), with mucus ...
Paul S. Cazier   +10 more
semanticscholar   +1 more source

Long-term impact of ivacaftor on mortality rate and health outcomes in people with cystic fibrosis

Thorax
Background Ivacaftor (IVA) has been shown to improve lung function and other clinical outcomes in people with cystic fibrosis (CF). A decade of real-world IVA availability has enabled the examination of long-term outcomes with this treatment.
C. Merlo   +8 more
semanticscholar   +1 more source

Ivacaftor

Reactions Weekly, 2023
openaire   +1 more source

Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in People with Cystic Fibrosis: A Clinical Trial

American Journal of Respiratory and Critical Care Medicine, 2022
Sarah Jane Schwarzenberg   +2 more
exaly  

The Effects of Ivacaftor on Bone Density and Microarchitecture in Children and Adults with Cystic Fibrosis

Journal of Clinical Endocrinology and Metabolism, 2021
Catherine Gordon   +2 more
exaly  

Ivacaftor

Reactions Weekly, 2014
openaire   +2 more sources

Ivacaftor

Reactions Weekly, 2017
openaire   +1 more source

Home - About - Disclaimer - Privacy